Thời sự

Chúng tôi cung cấp các tin tức mới nhất
từ thị trường tài chính và thế giới

Back
15 Tháng Hai
Alnylam Pharmaceuticals Inc. Q4 Loss Decreases, beats estimates

(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) revealed Loss for fourth quarter that decreased from the same period last year and beat the Street estimates.

The company's bottom line came in at -$137.87 million, or -$1.10 per share. This compares with -$207.49 million, or -$1.68 per share, in last year's fourth quarter.

Excluding items, Alnylam Pharmaceuticals Inc. reported adjusted earnings of -$96.64 million or -$0.77 per share for the period.

Analysts on average had expected the company to earn -$1.32 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter rose 31.2% to $439.72 million from $335.04 million last year.

Alnylam Pharmaceuticals Inc. earnings at a glance (GAAP) :

-Earnings (Q4): -$137.87 Mln. vs. -$207.49 Mln. last year. -EPS (Q4): -$1.10 vs. -$1.68 last year. -Analyst Estimates: -$1.32 -Revenue (Q4): $439.72 Mln vs. $335.04 Mln last year.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.